<DOC>
	<DOCNO>NCT02524964</DOCNO>
	<brief_summary>Approximately 60 patient ST-segment elevation myocardial infarction successfully treat primary percutaneous coronary intervention enrol randomized receive sodium tanshinone IIA sulfonate addition standard therapy volume/day normal saline . The primary endpoint variation LV end-diastolic volume index ( LVEDVi ) assess cardiac magnetic resonance imaging ( MRI ) baseline 6 month .</brief_summary>
	<brief_title>Sodium Tanshinone IIA Sulfonate Left Ventricular Remodeling Secondary Acute Myocardial Infarction</brief_title>
	<detailed_description>The primary endpoint determine whether sodium tanshinone IIA sulfonate could prevent LV remodel among patient completely reperfused AMI PCI , detect 6 month change LVEDVi measure use cardiac MRI compare placebo . Secondary endpoint include cardiac MRI measure variation microvascular obstruction , defect size , ventricular wall motion score , wall thickening , global LV ejection fraction , ventricular volume ( LV end-systolic/ diastolic volume ) myocardial perfusion interval . Furthermore , investigator determine variation ( change baseline ) biomarkers indicate myocardial fibrosis ( PICP , PIIINP , ICTP MMPs ) NT-ProBNP 1 6 month AMI . Additional efficacy endpoint include 6-minute walk test , New York Heart Association functional classification , Seattle Angina Questionnaire score incidence cardiovascular event ( define cardiogenic death , stroke , recurrent myocardial infarction , readmission account deterioration congestive heart failure unstable angina , target vessel revascularization ) 6-month follow-up also analyze evaluate efficacy sodium tanshinone IIA sulfonate treatment .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ventricular Remodeling</mesh_term>
	<mesh_term>Tanshinone</mesh_term>
	<criteria>1.Aged 18 year 80 year ; 2 . Firsttime myocardial infarction admission ; 3 . Presence STEMI successfully coronary recanalization PCI within 12 h symptom onset ; 4 . Willingness provide informed consent prior enrollment ; 5 . Patient able comply followup evaluation 1 . Contraindications performance CMRI [ pacemaker , implantable cardioverter/defibrillator device , cardiac resynchronization therapy ( CRT ) , claustrophobia , metal implant ( joint prosthesis , et al ) , history penetrative eye lesion ] ; 2 . Previous myocardial infarction , arrhythmia ( include atrial fibrillation bundle brunch block ) , significant valvular disease , hypertrophic cardiomyopathy ; 3 . Severe heart failure ( NYHA cardiac function class IV leave ventricular ejection fraction≤30 % ) cardiogenic shock ; 4 . Serious impairment renal function ( glomerular filtration rate ≤50 mL/min per 1.73 m2 ) ; 5 . Hypohepatia ( elevate alanine aminotransferase aspartate aminotransferase serum level ) ; 6 . Severe coagulopathy prior randomization ; 7 . Malignant tumor lifethreatening disease limited life expectancy &lt; 1 year ; 8 . Significant neuropsychopathic condition preclude write informed consent ; 9 . Pregnant lactating woman ; 10 . Known radiographic contrast sodium tanshinone IIA sulfonate allergy ; 11 . Be therapy immunosuppressant ; 12 . Currently participate investigational therapeutic device trial ; 13 . Clinical followup next half year possible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>leave ventricular remodeling</keyword>
	<keyword>cardiac magnetic resonance imaging</keyword>
	<keyword>acute myocardial infarction</keyword>
</DOC>